Royalty Pharma Retained Earnings (Accumulated Deficit) 2019-2024 | RPRX

Royalty Pharma retained earnings (accumulated deficit) for the quarter ending June 30, 2024 were $2.378B, a 5.56% increase year-over-year.

  • Royalty Pharma retained earnings (accumulated deficit) for 2023 were $2.518B, a 28.14% increase from 2022.
  • Royalty Pharma retained earnings (accumulated deficit) for 2022 were $1.965B, a 12.88% decline from 2021.
  • Royalty Pharma retained earnings (accumulated deficit) for 2021 were $2.255B, a 17.42% increase from 2020.

Royalty Pharma Retained Earnings (Accumulated Deficit) 2019-2024 | RPRX

  • Royalty Pharma retained earnings (accumulated deficit) for 2023 were $2.518B, a 28.14% increase from 2022.
  • Royalty Pharma retained earnings (accumulated deficit) for 2022 were $1.965B, a 12.88% decline from 2021.
  • Royalty Pharma retained earnings (accumulated deficit) for 2021 were $2.255B, a 17.42% increase from 2020.
Related Stocks
Company NameMarket
Cap
American Express (AXP)$186.4B
Blackstone (BX)$111.6B
Moody's (MCO)$88.3B
Orix Corp Ads (IX)$27.5B
Grupo Financiero Banorte SAB De CV (GBOOY)$21B
Brookfield Asset Management (BAM)$20.3B
Synchrony Financial (SYF)$19.3B
Equitable Holdings (EQH)$13.2B
Jefferies Financial Group (JEF)$12.5B
Daiwa Securities Group (DSEEY)$11.3B
XP (XP)$10.8B
Houlihan Lokey (HLI)$10.8B
Globe Life (GL)$9.6B
SouthState (SSB)$7.6B
Brookfield Wealth Solutions (BNT)$7.3B
Jackson Financial (JXN)$6.6B
StepStone Group (STEP)$6.2B
Blue Owl Capital (OBDC)$5.8B
Rithm Capital (RITM)$5.7B
Lazard (LAZ)$5.6B
Freedom Holding (FRHC)$5.6B
Virtu Financial (VIRT)$5B
Euronet Worldwide (EEFT)$4.5B
HA Sustainable Infrastructure Capital (HASI)$4.1B
AXOS FINANCIAL, INC (AX)$3.8B
Abrdn (SLFPY)$3.5B
Core Scientific (CORZ)$3.1B
PJT Partners (PJT)$3.1B
Community Financial System (CBU)$3.1B
StoneX Group (SNEX)$2.6B